Number of the records: 1  

Adenovirus type 5 (Ad5) is sequestered and inactivated by binding to coxsackievirus and adenovirus receptor (CAR) and complement receptor 1 (CR1) on human erythrocytes

  1. 1.
    0323764 - ÚMCH 2009 RIV US eng C - Conference Paper (international conference)
    Carlisle, R. C. - Di, Y. - Cerny, A. - Sonnen, A. - Sim, R. - Green, N. - Šubr, Vladimír - Ulbrich, Karel - Gilbert, R. - Fisher, K. - Finberg, R. - Seymour, L.
    Adenovirus type 5 (Ad5) is sequestered and inactivated by binding to coxsackievirus and adenovirus receptor (CAR) and complement receptor 1 (CR1) on human erythrocytes.
    [Adenovirus typu 5 (Ad5) je oddělen a deaktiviván vazbou na receptor coxsackie a adenoviru (CAR) a receptor 1 komplementu (CR1) lidských erythrocytů.]
    Human Gene Therapy. New Rochelle: Mary Ann Liebert Inc, 2008, s. 1191-1192. ISSN 1043-0342. E-ISSN 1557-7422.
    [Annual Congress of the European Society of Gene and Cell Therapy /16./. Brugge (BE), 13.11.2008-16.11.2008]
    EU Projects: European Commission(XE) 512087 - GIANT
    Institutional research plan: CEZ:AV0Z40500505
    Keywords : adenovirus * Coxsackie receptor * gene delivery
    Subject RIV: CD - Macromolecular Chemistry

    Human erythrocytes presents Coxsackie virus-adenovirus receptor providing an Ad5 sequestration mechanism that protects them against systemic virus infection but a virus binds via the fiber protein of Ad5 leading to close juxtaposition with the erythrocyte membrane. “Stealthing” of Ad5 using hydrophilic polymers enable circumvention of these natural virus traps.

    Lidské erythrocyty presentují Coxsackie virus-adenovirus receptor poskytující adenoviru (Ad5) oddělovací mechanizmus, který je chrání proti virální infekci, ale virus se váže prostřednictvím vláknitého proteinu, což vede k těsnému spojení s erythrocytovou membránou. Povrchová modifikace Ad5 pomocí hydrofilních polymerů umožní obejití této přirozené virální pasti.
    Permanent Link: http://hdl.handle.net/11104/0171626

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.